[1]Andrade M A, Bork P. 1995. HEAT repeats in the huntington’s disease protein. Nature Genetics, 11, 115-116. Cohen S E, Godoy V G, Walker G C. 2009. Transcriptional modulator NusA interacts with translesion DNA polymerases in Escherichia col i. Journal of Bacteriology, 191, 665-672. [2]Dames SA,Mulet J M, Rathgeb-Szabo K, HallMN, Stephan G. 2005. The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability. The Journal of Biological Chemistry, 280, 20558-20564. [3]Easley C A, Ben-YehudahA, Redinger C J, Oliver S L, Varum S T, Eisinger V M, Carlisle D L, Donovan P J, Schatten G P. 2010. mTOR-mediated activation of p70 S6Kinduces differentiation of pluripotent human embryonic stem cells. Cell Reprogram, 12, 263-273. [4]Haidinger M, Poglitsch M, Geyeregger R, Kasturi S, Zeyda M, Zlabinger G J, Pulendran B, Horl W H, Saemann M D, Weichhart T. 2010. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. Journal of Immunology, 185, 3919-3931. [5]Hay N, Sonenberg N. 2004. Upstream and downstream of mTOR. Genes and Development, 18, 1926-1945. [6]Kapahi P, Chen D, Rogers A N, Katewa S D, Li PW, Thomas E L, Kockel L. 2010. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metabolism, 11, 453-465. [7]Kim D H, Sarbassov D D, Ali S M, Latek R R, Guntur K V, Erdjument-Bromage H, Tempst P, Sabatini D M. 2003. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Molecular Cell, 11, 895-904. [8]Kobayashi H, Butler J M, O’Donnell R, Kobayashi M, Ding B S, Bonner B, Chiu V K, Nolan D J, Shido K, Benjamin L et al. 2010. Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of haematopoietic stem cells. Nature Cell Biology, 12, 1046-1056. [9]Li N, Lee B, Liu R J, BanasrM, Dwyer J M, IwataM, Li X Y, Aghajanian G, Duman R S. 2010. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 5994, 959-964. [10]de Marco A. 2006. Two-step metal affinity purification of double-tagged (NusA-His6) fusion proteins. Nauret Protocols, 1, 1538-1543. [11]de Marco G, Blandin S. 2004. The solubility and stability of recombinant proteins are increased by their fusion to NusA. Biochemical and Biophysical Research Communications, 322, 766-771. [12]Nallamsetty S, Waugh D S. 2006. Solubility-enhancing proteins MBP and NusA play a passive role in the folding of their fusion partners. Protein Expression and Purification, 45, 175-182. [13]Neasta J, Hamida B, Yowell S Q, Carnicella S, Ron D. 2010. Role for mammalian target of rapamycin complex 1 signaling in neuroadaptations underlying alcoholrelated disorders. Proceeding of the National Academy of Sciences of United States of America, 107, 10093-10098. [14]Pende M, Um S H, Mieulet V, Sticker M, Goss V L, Mestan J, Mueller M, Fumagalli S, Kozma S C, Thomas G. 2004. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Molecular Cell Biology, 24, 3112-3124. [15]Peterson R T, Beal P A, Comb M J, Schreiber S L. 2000. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. The Journal of Biological Chemistry, 275, 7416-7423. [16]Powell J D, Delgoffe G M. 2010. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity, 33, 301-311. [17]Schmelzle T, Hall M N. 2000. TOR, a central controller of cell growth. Cell, 103, 253-262. [18]Selman C, Tullet J M, Wieser D, Irvine E, Lingard S J, Choudhury A I, Claret M, Al-Qassab H, Carmignac D, Ramadani F, et al. 2009. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science, 326, 140-144. [19]Shaw R J, Cantley L C. 2006. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 441, 424-430. [20]Takahashi T, Hara K, Inoue H, Kawa Y, Tokunaga C, Hidayat S, Yoshino K, Kuroda Y, Yonezawa K. 2000. Carboxylterminal region conserved among phosphoinositidekinase-related kinases is indispensable for mTOR function in vivo and in vitro. Genes to Cells: Devoted to Molecular & Cellular Mechanisms, 5, 765-775. [21]Wang Z G, Fukazawa T, Nishikawa T, Watanabe N, Sakurama K, Motoki T, Hatakeyama S, Omori O, Ohara T, Tanabe S, et al. 2010. RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer. Oncology Reports, 23, 1167-1172. [22]Wang Z G, Wu Y J, Shorgen B. 2007. The mTOR signaling pathway and the regulation of cell growth. Acta Biophysica Sinaca, 22, 333-342. [23]Wullschleger S, Loewith R, Hall M N. 2006. TOR signaling in growth and metabolism. Cell, 124, 471-484. [24]Zoncu R, EfeyanA, Sabatini DM. 2011. mTOR: from growth signal integration to cancer, diabetes and ageing. Nature Reviews Molecular Cell Biology, 12, 21-35. |